Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology

References

• Borel JF, Feuer C, Gubler HU. Biological effects of cyclosporine A: a new antilymphocyte agent. Agents Act. 1976;6:468–475.
   PubMedGoogle Scholar
• Wong RL, Winslow CM, Cooper KD. The mechanism of action of cyclosporine A in the treatment of psoriasis. Immunol Today. 1993;14:69–74.
   PubMedGoogle Scholar
• Gupta AK, Brown MD, Ellis CN, Rocher LL, Fisher GJ, Baadsgaard O, Cyclosporine in dermatology. J Am Acad Dermatol. 1989;21:1245–1256.
   PubMedGoogle Scholar
• Cockburn IT, Krupp P. The risk of neoplasm in patients treated with cyclosporine A. J Autoimmun. 1989;2:723–731.
   PubMed Web of Science ®Google Scholar
• Mortimer PS, Dawber RPR, Morris PJ, Thompson JF, Ryan TJ. Hypertrichosis and multiple cutaneous squamous cell carcinomas in association with cyclosporine A therapy. J R Soc Med. 1983;76:786–787.
   Google Scholar
• Price ML, Tidman MJ, Ogg CS, MacDonald DM. Skin cancer and cyclosporine therapy. N Engl J Med. 1985;313:1420.
   Google Scholar
• Yajima Y, Sueki H, Oguro T, Iijima M. Effects of oral administration of cyclosporin A on skin carcinogenesis: a study using the two-stage carcinogenesis protocol in mice. Clin Exp Dermatol. 2008;33:478–483.
   PubMedGoogle Scholar
• Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporine A microemulsion for psoriasis, June 1996. Br J Dermatol. 1996;135:752–757.
   Google Scholar
• Lebwohl M, Ellis C, Gottleib A, Koo J, Krueger G, Linden K, Cyclosporine consensus conference. With emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464–475.
   PubMed Web of Science ®Google Scholar
• Fradin MS, Ellis CN, Voorhees J. Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol. 1990;23:1265–1273.
   PubMedGoogle Scholar
• Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211–216.
   PubMed Web of Science ®Google Scholar
• Oxholm A, Thompsen K, Menne T. Squamous cell carcinomas in relation to cyclosporine therapy of non malignant skin disorders. Acta Derm Venereol (Stockh). 1988;69:89–90.
   Google Scholar
• Green C, Hawk JL. Cutaneous malignancy related to cyclosporine A therapy. Clin Exp Dermatol. 1993;18:30–31.
   PubMed Web of Science ®Google Scholar
• Bos JD, Meinardi MM. Two distinct squamous cell carcinomas in a psoriasis patient receiving low-dose cyclosporine maintenance treatment. J Am Acad Dermatol. 1989;21:1305–1306.
   Google Scholar
• Bencini PL, Montagnino G, Crosti C, Sala F. Squamous-cell epitheliomata and cyclosporine treatment. Br J Dermatol. 1985;113:373–374.
   Google Scholar
• Van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol. 1997;136:275–278.
   PubMed Web of Science ®Google Scholar
• Piepkorn M, Kumasaka B, Krieger JN, Burmer GC. Development of human papillomavirus-associated Buschke-Lowenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis. J Am Acad Dermatol. 1993;29(2 Pt 2):321–325.
   Google Scholar
• Bulengo-Ransby SM, Sahn EE, Metcalf JS, Maize JC. Bowenoid change in association with graft-versus-host disease: a cyclosporine toxicity? J Am Acad Dermatol. 1994;31:1052–1054.
   Google Scholar
• Agnew KL, Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic associated with cyclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol. 2003;17:113–114.
   PubMed Web of Science ®Google Scholar
• Lain EL, Markus RF. Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patient treated with cyclosporine. J Drugs Dermatol. 2004;3:680–682.
   PubMedGoogle Scholar
• Mérot Y, Miescher PA, Balsiger F, Magnenat P, Frenk E. Cutaneous malignant melanomas occurring under cyclosporin A therapy: a report of two cases. Br J Dermatol. 1990;123:237–239.
   Google Scholar
• Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol. 2002;47(2 Suppl):S165–S167.
   Google Scholar
• Corazza M, Zampino MR, Montanari A, Altieri E, Virgili A. Primary cutaneous CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology. 2003;206:330–333.
   PubMedGoogle Scholar
• Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-Cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab. Br J Dermatol. 2003;149:170–173.
   PubMedGoogle Scholar
• Quéreux G, Renaut JJ, Peuvrel L, Knol AC, Brocard A, Dréno B. Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants. Acta Derm Venereol. 2010;90:616–620.
   Google Scholar
• Van Joost T, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol. 1988;118:183–190.
   PubMed Web of Science ®Google Scholar
• Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol. 1990;70:323–329.
   PubMed Web of Science ®Google Scholar
• Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137–140.
   PubMed Web of Science ®Google Scholar
• Munro CS, Levell NJ, Shuster S, Friedmann PS. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol. 1994;130:376–380.
   PubMed Web of Science ®Google Scholar
• Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994;31:68–74.
   PubMed Web of Science ®Google Scholar
• Van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994;130:634–640.
   PubMed Web of Science ®Google Scholar
• Garcovich A, Gatti M, Pompili A, Olivetti G, Catamo F. Short-term treatment with cyclosporin in severe psoriasis: four years of experience. Acta Derm Venereol Suppl (Stockh). 1994;186:92–93.
   Google Scholar
• Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol. 1996;135(Suppl 48):21–24.
   Google Scholar
• Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34:1016–1021.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin.Br Med J (Clin Res Ed). 1986;293:731–732.
   Google Scholar
• Cimitan A, Fantini F, Giannetti A. Clinical trial with cyclosporin A. Acta Derm Venereol Suppl (Stockh). 1989;146:159–162; discussion 162–163.
   PubMedGoogle Scholar
• Dubertret L, Perussel M, Robiola O, Feutren G. Cyclosporin in psoriasis. A long-term randomized study on 37 patients. Acta Derm Venereol Suppl (Stockh). 1989;146:136.
   Google Scholar
• Frappaz A, Haftek H, Thivolet J. Long-term treatment of severe psoriasis with low-dose cyclosporin: (2.5 mg/kg/day to 5 mg/kg/day). Acta Derm Venereol Suppl (Stockh). 1989;146:147.
   Google Scholar
• Timonen P, Friend D, Abeywickrama K, Laburte C, von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol. 1990;122(Suppl 36):33–39.
   Google Scholar
• Reitamo S, Erkko P, Remitz A, Lauerma AI, Montonen O, Harjula K. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol. 1993;129:1273–1279.
   PubMedGoogle Scholar
• Riccieri V, Sili Scavalli A, Spadaro A, Bracci M, Taccari E, Zoppini A. Short-term “cyclosporin A” therapy for psoriatic arthritis. Acta Derm Venereol Suppl (Stockh). 1994;186:94–95.
   Google Scholar
• Honeyman JF, Sanchez L, Valdes P. Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study. Int J Dermatol. 1995;34:583–588.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol. 1995;131:791–795.
   PubMed Web of Science ®Google Scholar
• Mahrle G, Schulze HJ, Brautigam M, Mischer P, Schopf R, Jung EG, Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol. 1996;135:752–757.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J. Clinical aspects: preliminary experience with a novel oral formulation of cyclosporin (Neoral). Br J Dermatol. 1996;135(Suppl 48):5–8.
   Google Scholar
• Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmune, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol. 1998;139:88–95.
   PubMed Web of Science ®Google Scholar
• Zachariae H, Abrams B, Bleehen SS, Brautigam M, Burrows D, Ettelt MJ, Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability. Dermatology. 1998;196:231–236.
   PubMed Web of Science ®Google Scholar
• Faerber L, Braeutigam M, Weidinger G, Mrowietz U, Christophers E, Schulze HJ, Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001;2:41–247.
   PubMedGoogle Scholar
• Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat. 2007;18:286–290.
   PubMed Web of Science ®Google Scholar
• Flyström B, Stenberg A, Bergbrant I-M. Methotrexate vs. cyclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008;158:116–121.
   Google Scholar
• Peluso AM, Bardazzi F, Tosti A, Varotti C. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients. Acta Derm Venereol Suppl (Stockh). 1994;186:90–91.
   PubMedGoogle Scholar
• Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol. 1997;136:527–530.
   PubMedGoogle Scholar
• Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, Leon-Dorantes G, Atakan N, Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol. 1999;141:283–291.
   PubMed Web of Science ®Google Scholar
• Ozawa A, Sugai J, Ohkido M, Ohtsuki M, Nakagawa H, Kitahara H, Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy. Eur J Dermatol. 1999;9:218–223.
   PubMed Web of Science ®Google Scholar
• Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52–58.
   PubMed Web of Science ®Google Scholar
• Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44:643–651.
   PubMed Web of Science ®Google Scholar
• Meinardi MM, de Rie MA, Bos JD. Oral cyclosporin A in the treatment of psoriasis. an overview of studies performed in The Netherlands. Br J Dermatol. 1990;122(Suppl 36):27–31.
   Google Scholar
• Reitamo S, Mustakallio KK. Cyclosporin in erythrodermic psoriasis. Acta Derm Venereol Suppl (Stockh). 1989;146:140–141.
   Google Scholar
• Powles AV, Baker BS, Valdimarsson H, Hulme B, Fry L. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol. 1990;122(Suppl 36):13–19.
   PubMedGoogle Scholar
• Fry L, Powles AV, Baker BS, Mcfadden J, Valdimarsson H. Long-term cyclosporin for psoriasis. Acta Derm Venereol. 1989;(Suppl 146):138–139.
   Google Scholar
• Griffiths CEM, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L. Long-term cyclosporine for psoriasis. Br J Dermatol. 1989;120:253–260.
   PubMedGoogle Scholar
• Fry L, Griffiths CEM, Powles AV, Baker BS, Valdimarsson H. Long-term cyclosporine in the management of Psoriasis. Transplant Proc. 1988;20(Suppl 4):23–25.
   Google Scholar
• de Rie MA, Meinardi MM, Bos JD. Analysis of side effects of medium- and low-dose cyclosporine maintenance therapy in psoriasis. Br J Dermatol. 1990;123:347–353.
   PubMed Web of Science ®Google Scholar
• Ross JS, Camp RD. Cyclosporin A in atopic dermatitis. Br J Dermatol. 1990;122(Suppl 36):41–45.
   Google Scholar
• Krupp P, Monka C. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol. 1990;122(Suppl 36):47–56.
   Google Scholar
• Christophers E, Mrowietz U, Henneicke HH, Farber L, Welzel D. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol. 1992;26:86–90.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology. 1993;187(Suppl 1):19–29.
   Google Scholar
• [No authors listed]. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology. 1993;187(Suppl 1):8–18.
   Google Scholar
• [No authors listed]. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology. 1993;187(Suppl 1):30–37.
   Google Scholar
• Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994;130:366–375.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Farber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol. 1995;33:470–475.
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996;35(5 Pt 1):710–719.
   Google Scholar
• Zonneveld IM, De Rie MA, Beljaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, Bos JD. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol. 1996;135(Suppl 48):15–20.
   PubMed Web of Science ®Google Scholar
• Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623–629.
   PubMedGoogle Scholar
• Shupack J, Abel E, Bauer E, Brown M, Drake L, Freinkel R, Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36(3 Pt 1):423–432.
   PubMedGoogle Scholar
• Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol. 1997;136:76–81.
   PubMed Web of Science ®Google Scholar
• Erkko P, Granlund H, Remitz A, Rosen K, Mobacken H, Lindelof B, Reitamo S. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol. 1998;139:997–1004.
   PubMed Web of Science ®Google Scholar
• Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet. 2001;358:1042–1045.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Cazzola M, Panni B, Turiel M, Fiorini T, Belai-Beyene N, Cherie-Ligniere EL. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int. 2002;21:234–238.
   PubMed Web of Science ®Google Scholar
• Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol. 2002;27:111–114.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Nakagawa H, Sugai J, Ozawa A, Ohkido M, Nakayama J, Long-term continuous versus intermittent cyclosporine: therapy for psoriasis. J Dermatol. 2003;30:290–298.
   PubMed Web of Science ®Google Scholar
• Chaidemenos G, Mourellou O, Avgoustinaki N, Papakonstantinou M. Intermittent vs. continuous 1-year cyclosporine use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2007;21:1203–1208.
   PubMed Web of Science ®Google Scholar
• Ojeda R, Sanchez RM, Massana J, Oliete R, Umbert P. Clinical experience with the use of cyclosporine A in psoriasis. Results of a retrospective study. J Dermatolog Treat. 2005;16:238–241.
   PubMed Web of Science ®Google Scholar
• Hijnen D, Berge OT, Timmer-de Mik L, Bruijnzeel-Koomen C, de Bruin-Weller M. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. Retrospective study of clinical and adverse effects of cyclosporin A treatment. J Eur Acad Dermatol Venereol. 2007;21:85–89.
   PubMed Web of Science ®Google Scholar
• Väkevä L, Reitamo A, Pukkala E, Sarna S, Ranki A. Long-term Follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol. 2008;88:117–120.
   Google Scholar
• Lockshin A. Lethality of human melanoma cells for normal mice immunosuppressed with cyclosporin A. Cancer Lett. 1987;35:159–166.
   Google Scholar
• Arellano F, Krupp PF. Cutaneous malignant melanoma occurring after cyclosporin A therapy. Br J Dermatol. 1991;124:611.
   Google Scholar
• Koo J, Lebwohl M. Letter to the editor. J Am Acad Dermatol. 1999;40:1016.
   Google Scholar
• Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1992;26:836–840.
   PubMed Web of Science ®Google Scholar
• Cliff S, Pettengell R, Gharge S, Marsden RA. B-cell lymphoma developing in a patient on cyclosporine for recalcitrant psoriasis. Br J Dermatol. 1999;140:749–782.
   Google Scholar
• Watabe H, Soma Y, Obara W, Murakami N, Kawase A, Mizukami T, Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm Venereol. 2006;86:184–185.
   PubMedGoogle Scholar
• Pielop JA, Jones D, Duvic M. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol. 2001;40:505–511.
   Google Scholar
• Thomas M, Chandi SM, George S, Pulimood S, Sitaram U. Sezary syndrome – unmasked by cyclosporine. Int J Dermatol. 1998;37:957–958.
   Google Scholar
• Zackheim HS, Koo J, LeBoit PE, McCalmont TH, Bowman PH, Kashani-Sabet M, Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol. 2002;47:155–157.
   PubMedGoogle Scholar
• Maddox AM, Kahan BD, Tucker S, Kerman R, Jordan RE. Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporine. J Am Acad Dermatol. 1985;12(5 Pt 2):952–956.
   Google Scholar
• Mougel F, Dalle S, Balme B, Houot R, Thomas L. Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis. Dermatology. 2006;213:239–241.
   Google Scholar
• Street ML, Muller SA, Pittelkow MR. Cyclosporine in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1990;23(6 Pt 1):1084–1089.
   Google Scholar
• Forman AB, Roenigk HH Jr, Caro WA, Magid ML. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol. 1989;125:515–519.
   PubMedGoogle Scholar
• Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999;140:237–242.
   PubMed Web of Science ®Google Scholar
• Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000;114:587–590.
   PubMed Web of Science ®Google Scholar
• Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778–783.
   PubMed Web of Science ®Google Scholar